Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity

• Status: Completed
• Trial end date: 2018-10-18
• Target enrollment: 0
• Participant gender: All

Summary

Patients with spondyloarthritis, already treated by TNF blocker (adalimumab, etanercept or infliximab), and in stable low disease activity for at least 6 months, will be randomized into 2 groups: either keeping on their usual treatment with stable doses or progressive spacing of injections of their treatment. Follow-up will be done every 3 months during 12 months, with regular monitoring of disease activity and, in patients from the group "spacing", modification of the rhythm of injections according to health state and predefined protocol.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Montpellier
• Treatments: Adalimumab; Antibodies, Monoclonal; Etanercept; Golimumab; Infliximab

Criteria

Inclusion Criteria:

• Adult patients with spondyloarthritis according to ASAS criteria

• Stable low disease activity for at least 6 months

• Already treated by TNF blocking drug (adalimumab, etanercept or infliximab)

Exclusion Criteria:

• Raised acute phase reactants

• participation in another clinical trial

• Structural progression of peripheral joint damage

• Scheduled surgery within 12 months

• pregnancy